Navigation Links
Antibody therapy prevents type 1 diabetes in mice

University of Pittsburgh investigators have successfully prevented the onset of type 1 diabetes in mice prone to developing the disease using an antibody against a receptor on the surface of immune T-cells. According to the investigators, these findings, which are being published in the January issue of the journal Diabetes, have significant implications for the prevention of type 1 diabetes.

More than 700,000 Americans have type 1 diabetes, an autoimmune disorder in which the body errantly attacks the insulin-producing cells of the pancreas, causing chronically elevated levels of sugar in the blood, leading to blindness, kidney failure, heart disease and nerve damage. Previously known as juvenile diabetes, type 1 diabetes is usually diagnosed at a very early age, but in some cases it can be diagnosed in adulthood.

In this study, the Pitt researchers treated non-obese diabetic (NOD) mice with an antibody -- a type of protein produced by the immune system that recognizes and helps fight infections and other foreign substances in the body -- directed against a receptor known as CD137 on the surface of a type of immune cell called T-cells. Treating NOD mice with the anti-CD137 antibodies significantly suppressed the development of diabetes, whereas most of the control mice developed diabetes by the time they were six months old.

Interestingly, the antibody therapy did not appear to cure the NOD mice because the researchers were still able to see lymphocytes in their pancreatic islets, a tell-tale sign of pancreatic inflammation and autoimmunity. In addition, when the researchers isolated cells from the spleens of the antibody-treated mice and injected these cells into immune-deficient NOD mice, seven of the nine recipient mice developed type 1 diabetes, indicating that the donor mice still harbored pathogenic T-cells. On the other hand, when the researchers transferred a certain subset of T-cells from anti-CD137-treated mice that expressed t wo other receptors known as CD4 and CD25 to other immune-deficient NOD mice, it prevented the onset of diabetes in the recipient mice.

According to senior author William M. Ridgway, M.D., assistant professor in the University of Pittsburgh School of Medicine's department of rheumatology and clinical immunology, this therapy, if given early enough, may offer a viable method for preventing the onset of type 1 diabetes in genetically at-risk people.

"Our studies and others suggest that CD137 plays a significant role in the development of and genetic predisposition to type 1 diabetes. In this study, for the first time, we have demonstrated that CD137 antibody therapy can suppress the development of type 1 diabetes in mice and that the effect is dependent on the induction of a certain subset of regulatory T-cells. If we can demonstrate this same genetic predisposition and therapeutic effect in human type 1 diabetes patients, then this may prove to be a significant step toward preventing this disease before it can take hold," he explained.


Source:University of Pittsburgh Medical Center

Related biology news :

1. Antibody extends life of mice with breast cancer
2. Antibody signal may redirect inflammation to fuel cancer
3. Adding Radiation Therapy To Chemotherapy Improves Survival In Patients With High-risk Breast Cancer
4. Columbia research lifts major hurdle to gene therapy for cancer
5. Combination therapy boosts effectiveness of telomere-directed cancer cell death
6. Gene therapy converts dead bone graft to new, living tissue
7. Study identifies predictors of HIV drug resistance in patients beginning triple therapy
8. New imaging method gives early indication if brain cancer therapy is effective, U-M study shows
9. Muscle-targeted gene therapy reverses rare muscular dystrophy in mice
10. New therapy for HIV/AIDS eliminates needles and excessive toxicity
11. New Treatment Rivals Chemotherapy For Lymphoma, Study Finds
Post Your Comments:

(Date:8/23/2017)... , Aug. 23, 2017  The general public,s help is being ... microbiome—the bacteria that live in and on the human body –and are ... The Microbiome ... the human microbiome, starting with the gut. The project's goal is to ... Photo credit: IBM ...
(Date:6/14/2017)... June 15, 2017  IBM (NYSE: IBM ) is introducing ... event dedicated to developing collaboration between startups and global businesses, ... 15-17. During the event, nine startups will showcase the solutions ... various industries. France ... market, with a 30 percent increase in the number of ...
(Date:4/24/2017)... 2017 Janice Kephart , former ... Strategy Partners, LLP (IdSP) , today issues the ... Trump,s March 6, 2017 Executive Order: Protecting ... can be instilled with greater confidence, enabling the ... refugee applications are suspended by until at least ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... ... October 11, 2017 , ... ComplianceOnline’s Medical Device Summit is back for its ... 2018 in San Francisco, CA. The Summit brings together current and former FDA office ... directors and government officials from around the world to address key issues in device ...
(Date:10/11/2017)... ... , ... Disappearing forests and increased emissions are the main causes of the ... Especially those living in larger cities are affected by air pollution related diseases. , ... pollution-affected countries globally - decided to take action. , “I knew I had to ...
(Date:10/10/2017)... CA (PRWEB) , ... October ... ... a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today ... of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration ...
(Date:10/10/2017)... SomaGenics announced the receipt of a Phase ... (Single Cell), expected to be the first commercially available ... from single cells using NGS methods. The NIH,s recent ... development of approaches to analyze the heterogeneity of cell ... for measuring levels of mRNAs in individual cells have ...
Breaking Biology Technology: